When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely
Wiener klinische Wochenschrift · 2026-02 · 138 (3-4) · 121-123
DOI: 10.1007/s00508-025-02583-x ↗Kurz gefasst
Fallbericht in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 18.08.2025. Verfasst von T Vukić Bilić und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Various adverse reactions to elexacaftor/tezacaftor/ivacaftor (ETI) therapy have been documented in the literature. Here, we present the first reported case in Croatia of severe rash following ETI therapy in a 19-year-old female cystic fibrosis (CF) patient. There were two attempts to introduce ETI therapy, spaced two months apart, both of which resulted in diffuse maculopapular rash, in the second attempt, the rash appeared on the same day as re-initiation. Given the clinical benefits of ETI treatment, andinspired by several case reports on drug desensitization, in July 2023, we started the patient on a modified 3-day-tolerance induction protocol which was successful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia.
- Department of Pharmacy, University Hospital Centre Zagreb, Zagreb, Croatia.
- Division for Clinical Pharmacology and Therapeutics, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Croatia.
- Cystic fibrosis center for children and adults, University Hospital Centre Zagreb, Zagreb, Croatia.
- Clinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia. adugac71@gmail.com.
Zitieren
APA
Vukić Bilić, T., Alebić, M., Banić, M., Darapi, D., Likić, R., Ganza, M., Rnjak, D., Tješić-Drinković, D., & Vukić Dugac, A. (2026). When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely. Wiener klinische Wochenschrift, 138(3-4), 121-123. https://doi.org/10.1007/s00508-025-02583-x
Vancouver
Vukić Bilić T, Alebić M, Banić M, Darapi D, Likić R, Ganza M, et al. When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely. Wiener klinische Wochenschrift. 2026;138(3-4):121-123. doi:10.1007/s00508-025-02583-x
BibTeX
@article{VukiBili2026,
author = {Vukić Bilić, T and Alebić, M and Banić, M and Darapi, D and Likić, R and Ganza, M and Rnjak, D and Tješić-Drinković, D and Vukić Dugac, A},
title = {When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely},
journal = {Wiener klinische Wochenschrift},
year = {2026},
volume = {138},
number = {3-4},
pages = {121--123},
doi = {10.1007/s00508-025-02583-x}
}
EUVIMED